Abstract:Kanako Shinada, Shuji Murakami Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan Correspondence: Shuji Murakami, Department of Thoracic Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan, Tel +81-45-520-2222, Email Perioperative therapy for non-small cell lung cancer has been studied extensively in a bid to improve overall survival, as approximately half of the patients with surgically resectable tumors at the time of diagnosis relapse. In recent years, immune checkpoint inhibitor therapies, such as the anti-programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) blockade, have contributed to achieving an improved overall survival of patients with advanced stage lung cancer. Thus, the development of this treatment strategy has considerable potential to precipitate a breakthrough in cancer immunotherapy. PD-1/PD-L1 blockade has several potential immunological benefits when used as a neoadjuvant therapy. However, there are concerns associated with this neoadjuvant therapy. Many studies have reported its efficacy, but there is limited evidence regarding the long-term survival of patients. Similarly, it is unclear whether existing biomarkers are adequate for monitoring the prognosis of patients, or if new biomarkers are required. In this article, we present recent reports on neoadjuvant PD-1/PD-L1 blockade therapy and discuss its future challenges. Keywords: non-small cell lung cancer, NSCLC, neoadjuvant, immune checkpoint inhibitor, ICI, programmed death 1, PD-1, programmed death ligand 1, PD-L1 Approximately 30% of patients with lung cancer are eligible for surgical resection. 1,2 For early-stage (stage I–IIIA) non-small cell lung cancer (NSCLC), surgical resection is the mainstay of treatment. 3,4 However, even with complete resection, there are high rates of recurrence and metastasis. 5 This is probably due to the presence of distant micrometastases; 6,7 therefore, systemic treatment is important for improving the prognosis of NSCLC. In some trials comparing neoadjuvant and adjuvant chemotherapy, the survival benefit was not demonstrated between these two strategies; 8,9 however, unlike in the adjuvant setting, the completion rate of chemotherapy in the neoadjuvant setting was maintained without increasing toxicity. Neoadjuvant chemotherapy thus has some advantages over adjuvant chemotherapy. Neoadjuvant therapy can generate the possibility of resection in patients with large tumors that are considered inoperable at diagnosis or in tumors that are connected to major organs. This is also expected to reduce the incidence of micrometastases. These are expected to increase the possibility of complete resection. Furthermore, it allows rapid assessment of tumor and surrounding tissue response to treatment. Conversely, the disadvantages of neoadjuvant chemotherapy include the following; risk of missing the opportunity for resection in patients whose tumors progressed without response to chemotherapy, the possibility of difficulty in continuing subsequent treatment including surgery due to adverse events, and, in the worst case, the possibility of treatment-related death in the worst case. In recent years, cancer immunotherapy targeting immune checkpoints, such as the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) signaling pathway, and molecular targeted therapy have dramatically improved the prognosis of patients with advanced NSCLC. 10–14 However, the role of immune checkpoint inhibitors (ICIs) in the early stages is poorly understood. Neoadjuvant PD-1/PD-L1 blockade therapy is also a topic of interest, and the results of clinical trials have been reported. The next section reviews the merits and feasibility of neoadjuvant PD-1/PD-L1 blockade regimens and discusses the perioperative treatment of immunotherapy as well as future problems and perspectives. To activate the anticancer immune response and destroy cancer cells, a series of stepwise events called the cancer-immunity cycle must be initiated. The released neoantigens created by oncogenic processes are captured and processed by dendritic cells. 15 Subsequently, dendritic cells migrate to the draining lymph nodes to prime and activate effector T-cell responses against cancer-specific antigens. 16,17 Therefore, draining lymph nodes are assumed to be the first lymph nodes to which cancer cells metastasize from the primary lesion, as well as the lymph nodes necessary for the activation of local tumor immunity. A potential advantage of neoadjuvant immunotherapy is the stimulation of effective systemic immunity. This means that it could potentially be effective in eradicating residual metastatic disease after surgical removal of the primary tumor. In a study of metastatic breast cancer in mouse m -Abstract Truncated-

Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer

Neoadjuvant immunotherapy based on PD-1/L1 Inhibitors for gastrointestinal tumor: a review of rationale and clinical advances

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer

Neoadjuvant Long-Course Chemoradiation Plus PD1 Blockade for Locally Advanced Rectal Cancer: Results of a Phase 2, Open-Label, Randomized Controlled Trial.

[Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors]

Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review

The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review

Neoadjuvant PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker.

Total Neoadjuvant Treatment and PD-1/PD-L1 Checkpoint Inhibitor in Locally Advanced Rectal Cancer

A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer

Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations

PD-1/PD-L Blockade in Gastrointestinal Cancers: Lessons Learned and the Road Toward Precision Immunotherapy

Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer

Tumor Cell PD-L1 Predicts Poor Local Control for Rectal Cancer Patients Following Neoadjuvant Radiotherapy

Efficacy and Safety of Preoperative Immunotherapy in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Gastrointestinal Malignancies

Oral delivery of anti-PD-L1 antibody for cancer immunotherapy against orthotopic colorectal tumors

Organ Preservation in Locally Advanced Colorectal Cancer with Microsatellite Instability-High after Immunotherapy

Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study

Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis